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ABSTRACT 
Background: Depression is a large societal problem. People suffering from depression are 
heterogeneous and have a high degree of comorbid conditions. Pharmacological treatment is 
widespread, but not effective for all sufferers, and patients often have a preference for 
psychological treatment. There are effective psychological treatment alternatives, but access to 
treatment is low. Individually tailored internet-based treatment has the ability to target several 
conditions within the same treatment. It has shown promising effects on depression and anxiety 
but needs to be further evaluated against other interventions. The effects of specific treatment 
components also need to be explored. 
Aims: The aims of this thesis were to evaluate the effects and cost-effectiveness of individually 
tailored internet-based treatment compared to other treatment alternatives, to compare its 
effects to disorder-specific benchmark treatments, and to explore if compliance to treatment 
components for specific conditions predict reductions in the targeted symptoms.  
Methods: Study I-IV were based on the randomized trial REGASSA (n = 946) where an 
individually tailored internet-based treatment (TAIL) were compared to structured physical 
exercise (PE) and to treatment as usual in primary care (TAU). In Study I, the effects of TAIL 
and PE on depression symptoms were evaluated against TAU. Study II evaluated the cost-
effectiveness of TAIL and PE against TAU. In Study III, TAIL was compared to similar, but 
disorder-specific, benchmark treatments for depression (n = 2358), panic disorder (n = 1176) 
and social anxiety disorder (n = 1335). In Study IV, the participants’ compliance to the different 
specific components in the TAIL-intervention were rated, and related to symptom reductions.  
Results: The effects of TAIL on depression symptoms were large (g = 1.47, 95% CI 1.29-
1.66), and there were significantly larger reductions in depression symptoms than in the TAU-
group. There were no significant differences in effects on depression symptoms between TAIL 
and PE. TAIL and PE had 90 and 76 % probabilities respectively, of being cost-effective 
compared to TAU, given standard health care provider willingness to pay-thresholds. The 
effects of TAIL on depression symptoms were non-inferior to disorder-specific internet-based 
treatment. The effects of TAIL on panic or social anxiety symptoms however, could not be 
concluded to be non-inferior to disorder-specific treatment. Overall compliance with TAIL was 
strongly related to symptom reductions in depression, panic, social anxiety, stress and 
insomnia, weakly related to reductions in worry, but not related to reductions in pain symptoms. 
Compliance to specific components for social anxiety was related to reductions in specific 
social anxiety symptoms. Compliance to specific components for stress and insomnia were 
particularly important since they were related to both specific symptom reductions and 
reductions of depressive symptoms.   
Conclusions: The results in this thesis support that individually tailored internet-based 
treatment is an effective and cost-effective treatment alternative to be considered for 
implementation. It is as effective as the disorder-specific internet-based treatments for 
depression already used in routine care, but more comparisons are needed to conclude if it is 
as effective as disorder-specific anxiety treatments. Since specific treatment components for 
stress and insomnia were important for both specific and depressive symptom reductions, it is 
probable that individual tailoring for these conditions is worthwhile in the treatment of 
depression. 
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1 INTRODUCTION 
“Ever since psychology, thanks to its impartial investigation of the facts, has risen to the status 
of a natural scientific discipline, it has succeeded in creating strictly empirical research 
methods that might, upon further development, be applied to the difficult study of morbid 
mental states.” 
Emil Kraepelin, 1887. 
1.1 PSYCHOLOGY IN PSYCHIATRY 
Emil Kraepelin (1856-1926) was an influential German psychiatrist, famous for separating 
affective disorders from what is now known as schizophrenia when classifying mental 
illnesses. Kraepelin is also known for considering the affective disorders as a spectrum which 
included dimensions, such as mania. In the late 20th century, Kraepelin became an icon for 
medical-model psychiatrists (sometimes known as neo-Kraepelinians) who needed a historical 
role model when debating the then dominant psychoanalytic theories of Sigmund Freud. 1  
The real Kraepelin however, was not a pure medical-model psychiatrist. The name of his 
doctoral thesis from 1882 translates as The Place of Psychology in Psychiatry, and he argued 
for there to be such a place many times, such as in his inaugural lecture at the University of 
Dorpat in 1887, which the quote above is an excerpt from. The quote highlights that the kind 
of psychology Kraepelin wanted in psychiatry was empirical psychology, a subsection of 
natural science, and not the introspective psychology such as that of the psychoanalysts. 
Kraepelin’s interest in psychology was influenced by working in the experimental 
psychologists Wilhelm Wundt’s newly opened laboratory in Leipzig, 2 where he often 
preferred to spend time doing experiments instead of doing clinical work during his early 
career. 3   
Following my namesake, I will make my thesis an attempt to make place for increased amounts 
of psychology in psychiatry. More precisely, my aim is to make use of knowledge based on 
empirically driven psychological science (psychology), in the treatment of mental disorders 
(psychiatry).  
1.2 MAJOR DEPRESSIVE DISORDER 
The merits of Kraepelinian dimensional definitions of mental illness are sometimes argued for 
by researchers, but categorical definitions are currently the most used in clinical practice. 4 
Hence, we will now take a look at the most widely used categorical definition of the most well-
known of mental illnesses: depression. The criteria for a major depressive episode (major 
depression) in The Diagnostic and Statistical Manual of Mental Disorders 5th ed. (DSM–5) 5 
follows in Table 1. The patient needs to fulfill A, B and C to reach the diagnostic criteria for 
major depression.  
 2 
Table 1. DSM-5 criteria of major depression 
 
1.3 THE IMPACT OF DEPRESSION FOR INDIVIDUALS AND SOCIETY 
Depression, as defined in the DSM diagnostic system, has a large impact on mortality, 
disability and quality of life, burdening both individuals and societies worldwide. 6 The World 
Health Organization projects major depression to be the leading cause of burden of disease in 
2030. 7 In Sweden, clinically significant depressive symptoms are experienced by 10.8 % of 
the adult population, and 5.2 % qualifies as having major depression. 8 Depression is also 
A. Five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms is 
either (1) depressed mood or (2) loss of interest or pleasure. 
Note: Do not include symptoms that are clearly due to a general medical condition, or 
mood-incongruent delusions or hallucinations. 
 Depressed mood most of the day, nearly every day, as indicated by either subjective 
report (e.g., feels sad or empty) or observation made by others (e.g., appears 
tearful).  
 Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day, nearly every day (as indicated by either subjective account or observation 
made by others). 
 Significant weight loss when not dieting or weight gain (e.g., a change of more than 
5 percent of body weight in a month), or decrease or increase in appetite nearly 
every day.  
 Insomnia or hypersomnia nearly every day. 
 Psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down). 
 Fatigue or loss of energy nearly every day. 
 Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick). 
 Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others). 
 Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide. 
B. The symptoms cause clinically significant distress or impairment in social, occupational 
or other important areas of functioning. 
C. The symptoms are not due to the direct physiological effects of a substance (e.g., a drug 
of abuse, a medication) or a general medical condition (e.g., hypothyroidism). 
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associated with high societal costs, both in Sweden and internationally. 9,10 These costs consist 
of direct costs such as health care resource use, but also large indirect costs such as when 
sufferers are on sick-leave or have lower productivity at work. 
1.4 HETEROGENEOUS DEPRESSION 
The categorical DSM-type definition of major depression has the advantage of being 
unambiguous; either you have it or not, but it also has some problems to consider. One artifact 
of the above DSM-definition of depression is that many different symptoms are described as 
being part of the same disorder. 11 An example of this would be that a patient with insomnia 
and weight loss could belong to the same category (major depression) as a patient with 
hypersomnia and weight gain.  
Another artifact of the categorical definition is that a patient with a diagnosis of major 
depression often qualifies for one or a number of other distinct DSM-diagnoses. This is often 
referred to as psychiatric comorbidity. Some recent research into the interactions of psychiatric 
symptoms describes how comorbidity can occur when diagnoses such as major depression and 
generalized anxiety disorder share a large part of DSM-symptom criteria. 12 
1.5 DEPRESSION AND COMORBIDITY 
Depression and anxiety often co-occur. In the United States 58 % of patients with major 
depression also has an anxiety disorder, and as many as 95 % show anxiety symptoms. 13 In a 
survey of the Swedish general population, over 50 % who had clinically significant symptoms 
of depression or anxiety, had both problems simultaneously. 8 In a survey of primary care 
visitors, 60 % who listed psychological distress as the main reason for visit, reported a high 
degree of symptoms in at least two problem areas such as depression, anxiety or stress/fatigue. 
14 In a register study of a Swedish primary care population (N = 5 397 675) diagnosed comorbid 
disorders were high in patients with major depression, especially for anxiety disorders (40.7 
%) and adjustment disorder (32.1 %). 15 Figure 1 further illustrates the high comorbidity 
between depression and three common anxiety disorders. 
Pain is highly comorbid to depression. 65 % of depressed patients have been estimated to have 
at least some pain symptoms, and conversely do around 27 % of pain patients in a primary care 
context fulfill the diagnostic criteria for major depression. 16  
Insomnia is also very common in depression. Up to 90 % of depressed patients reports insomnia 
symptoms. 17 In contrast, only 14 % of insomnia patients qualifies as having major depression, 
implying that insomnia is the more common condition in the population. 18  
Since there is, as we have seen, a risk of artifactual relationships between depression and other 
conditions, causal relationships have to be further examined. There is, for example, some recent 
evidence of a causal relationship between treating insomnia symptoms and preventing 
depression in the longer term. 19 
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Figure 1. The concurrence between major depression and anxiety disorders is high. The figure 
aims to illustrate the overlap of estimated lifetime prevalence of major depression, in patients 
with generalized anxiety disorder (GAD), panic disorder or social anxiety disorder. The size of 
the bubbles does not represent absolute prevalence estimates. All estimates are from Gorman 
J. “Comorbid depression and anxiety spectrum disorders”. 13 
1.5.1 Conditions and disorders 
Since having comorbid disorders can be a non-intended side-effect of the diagnostic system, 
and having multiple mental disorders is possibly stigmatizing, we shall in this thesis aim to 
consider the comorbidity of depression as one of co-occurring psychological conditions, and 
not of multiple mental disorders. A condition is here defined as a broader term than disorder, 
that encompasses states of health that is not considered pathological, but still has implications 
for treatment (an example of such a condition would be pregnancy). The condition depression 
is additionally not the same as the disorder major depressive disorder. A condition is here 
considered not as categorical, but as a dimensional or pseudo-dimensional construct, where 
you can have no, mild, moderate or severe symptoms of the condition. 20  
The reason for using dimensional constructs of various conditions in depression is the 
mentioned high somatic and anxious comorbidity in people who present with depression in 
primary care or other general medical settings. 21 A patient seeking care for depression who is 
moderately anxious or stressed, but only mildly depressed, might for example not receive 
treatment because the depression is considered sub-clinical, although the aggregated burden is 
quite severe. By considering several dimensional conditions, we aim to better describe the 
Major 
depression
GAD
Panic 
disorder
Social 
anxiety 
disorder
62% 
27% 50% 
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problems facing the majority of patients with psychological complaints than we would be able 
to by using categorical definitions only. Figure 2 illustrates a population with depression and 
comorbid conditions. 
 
Figure 2. Depression and comorbid conditions. Schematic illustration on the relation between 
depressive symptoms and the symptoms of the other conditions assessed in the individually 
tailored internet-based treatment of this thesis. The size of the bubbles, or of the overlap with 
the depression bubble, does not represent the size of the comorbidities. In reality, the comorbid 
conditions also overlap each other. 
1.6 PHARMACOLOGICAL TREATMENT 
1.6.1 Antidepressants 
To put psychological treatments in context, we first need to mention the currently dominating 
treatment paradigm of pharmacological treatment. The prescription of antidepressant 
medication is widespread in primary care. Antidepressants are with 79.4 % the most common 
treatment prescribed to people with depression in Swedish primary care. 15 In the United States, 
only one out of five prescriptions of antidepressants is done by a psychiatrist, and in most cases 
there is no diagnosis of depression. 22 Primary care patients who are prescribed antidepressants 
without a diagnosis of depression are often elderly, with somatic complaints, and milder mood 
or anxiety symptoms. 22  
Depression
Worry
Panic
Social 
anxiety
Stress
Insomnia
Pain
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A Cochrane review of randomized trials of antidepressants in primary care settings found that 
antidepressants of both the older tricyclic type, and the newer selective serotonin reuptake 
inhibitor type (SSRI), were more effective than placebo in lowering depression levels. 23 These 
results were however based on a sample of primary care patients with a diagnosis of major 
depression, and not the whole diverse population currently receiving antidepressant treatment 
in primary care. The advantage over placebo was on average small with a number needed to 
treat of 8-10 depression patients on antidepressants for one additional responder. 24 Active 
treatment also seem to have somewhat increased the risk of dropping out because of negative 
side effects. 24  
In addition to the small effect compared to placebo, a critique of the most widely used SSRI 
type of antidepressants is that they are used on everything from heterogeneous “primary care 
depression” to very severe depression (melancholia), in spite of there probably being different 
biological underpinnings for all the different states that share the name depression. 25  
Proponents of SSRI use for depression has pointed out that the response to SSRI seems to be 
heterogeneous rather than universally poor. 26 Since the effects of different SSRI types affect 
different depression patients differently, and a quarter of patients also show a poorer response 
on SSRI than they would have on placebo, pharmacological treatment needs to be personalized. 
One effect of personalization is that patients who seem to be better off avoiding SSRIs should 
be identified and diverted to other treatments for depression. 26 
1.6.2 Other pharmacological treatments 
Benzodiazepines have a rapid anxiolytic and sedating effect, and can be efficacious in the short-
term treatment of anxiety disorders such as generalized anxiety disorder, panic disorder and 
social anxiety disorder. 27 Benzodiazepines are extensively used in primary care for anxiety 
and insomnia, but tolerance and dependence are common negative side-effects, together with 
risks of hazardous sedation and cognitive impairment. 28 Benzodiazepines may also interfere 
with the psychological treatment of anxiety and insomnia. 29,30 Some commonly prescribed 
pain medications, i.e. opioids, also have great risks of tolerance and dependence, and the 
widespread legal prescription has resulted in an increased use of illegal opioids. 31,32  
1.7 PSYCHOLOGICAL TREATMENT 
In addition to the risks of side-effects from medications prescribed for common psychological 
conditions, there is a preference in a majority of patients for psychological treatment over 
pharmacological. 33 This suggests that access to effective and safe psychological treatment 
should be a priority. Psychological treatment is now also often prioritized before 
pharmacological treatment in national guidelines for common mental health disorders, such as 
the UK NICE guidelines, 34 and Swedish national guidelines. 35 
Although negative side-effects are traditionally less well described in psychological compared 
to pharmacological treatments, they are far from negligible. 36,37 In some psychological 
interventions, such as the debriefing of trauma victims, the negative effects even seems to 
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outweigh the positive effects. 38 But negative side-effects are also possible results of treatment 
components that have a solid evidence base of their effectiveness. Some examples would be 
patients who deteriorate, or who discontinue their otherwise effective treatment early, as a 
result of not coping with the emotional stress accompanying some treatment components, such 
as exposure. 37 Negative side-effects, such as deterioration, therefore needs to be estimated in 
studies of psychological treatment, to be able to make a fair comparison to other treatment 
alternatives. 
1.7.1 Psychological treatment for depression 
The current versions of psychological treatment are known by many different names. A meta-
analysis of psychological treatments for depression by Cuijpers and colleagues discriminates 
between a few major subtypes of treatment that have some evidence: Cognitive behavioral 
therapy (CBT), behavioral activation, interpersonal psychotherapy, psychodynamic therapy, 
problem solving therapy, and supportive counselling. 39 These types of treatment are, according 
to the meta-analysis, all effective in reducing symptoms of depression compared to controls, 
but with some varying efficacy. When looking at the proportion of participants not meeting 
criteria for major depression after treatment there was a slight difference between the most 
successful treatment behavioral activation (74 %) and the least successful treatment supportive 
counselling (49 %). 39 The results of different psychological treatments also needs to be 
contrasted against the surprisingly good results of active control conditions (43 %), and the not 
so good waiting list control conditions (17 %).  
There are both differences and common factors in these subtypes of psychological treatment. 
The most extensively researched type of psychological treatment for depression, CBT, has 
since the early days of Aaron Beck included cognitive reappraisal as well as elements of 
behavioral activation, interpersonal aspects, problem solving, and supportive aspects. 40 This 
means that many of the above mentioned subtypes of psychological treatment are actually 
included as components within the CBT-family of interventions. 
The treatment compliance, i.e. the extent to which you actually perform the homework of the 
components, has been related to outcome in CBT for depression, and the relation seemed to be 
that better compliance caused larger symptom reductions. 41 Currently there is no consensus on 
which components, or combinations of components, that are the most effective at reducing 
depression. 42 Future dismantling studies may provide new valuable insights into the role of 
different components in psychological treatment. 43 
The treatment component of behavioral activation is however already a promising candidate of 
being a sufficient treatment component in its own for many people with depression. Behavioral 
activation usually refers to the structured scheduling of pleasant and important activities, and 
the reduction of the avoidance behaviors that are common in depression. In 1996 a dismantling 
study of the components in Becks CBT for depression suggested that the behavioral activation 
component was as effective as the full treatment package. 44 A more recent study has suggested 
that behavioral activation might even be superior to some other types of psychological 
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treatment for the more severely depressed patients. 45 In addition to being a possibly sufficiently 
effective component of psychological treatment, behavioral activation also has the advantage 
of being uncomplicated, time-efficient and not requiring complex skills from either participants 
or therapists. 44  
1.7.2 Psychological treatment components for other common conditions 
Interventions belonging to the CBT-family of psychological treatment are also efficacious for 
anxiety disorders, and when the target is the reduction of anxiety, the treatment component of 
exposure seems critical. 46 Exposure refers to systematically and gradually approaching 
situations and stimuli that evoke an excessive fear response. For some anxiety disorders, such 
as social anxiety, exposure alone has been shown to be at least as effective as full CBT. 46 
Stress management interventions based on components in the CBT-tradition are also effective 
in reducing long-term negative effects of stress. 47 A core treatment component for effective 
stress management appears to be to schedule more time for recovery 48,49  
Psychological treatments classified as CBT also have evidence for the treatment of insomnia 
and pain. 50 For pain, important treatment components include education about pain, relaxation 
training and activity scheduling. 50 For insomnia symptoms, the component of sleep restriction 
(to restrict the time in bed to the time asleep) appears to be critical, 51 together with stimulus 
control. 52 
In summary, psychological treatment has evidence for many conditions that are often comorbid 
to depression, but the core components of those treatments vary with the specific symptoms 
being targeted.  
1.7.3 Guided self-help and internet-based treatment 
Psychological treatments offered as guided self-help are often seen as a way to improve access 
to treatment as well as reducing cost of treatment. These treatments can be administered 
through psychoeducation and homework assignments in self-help-books, with guidance by 
phone or visits face to face. But a convenient way to add guidance, structure or information 
feedback is to give guided self-help as entirely internet-based treatments. 53  
Internet-based treatment of depression has been shown to have a small effect also when 
administered without therapist guidance, but minimal guidance by a therapist is often regarded 
as an effective way to boost adherence and efficacy of treatment. 54,55 The additive effects of 
this guidance seems to be maintained when given by a technician as well as a trained clinician, 
56 and even when the guidance consisted automated messages, reinforcing progress and 
reminding about availability of new material. 57 
Adherence to treatment, defined as how much of the intervention individuals access, is an 
important predictor in internet-based treatments for depression and anxiety. 58 A study of a 
guided self-help treatment for insomnia, suggested that the boosting effect of guidance was 
mediated by how much the therapist succeeded in involving the participant in using the most 
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relevant treatment components, in this case sleep restriction and stimulus control. 59 When 
given together with guidance (or other structure that promotes adherence up to comparable 
levels), self-help treatments seem to be as effective as the more traditional face to face-
treatments for depression and some anxiety disorders. 60  
1.7.4 Internet-based treatment in routine care settings 
Internet-based treatment has also been tested in a routine care-context. Although given from a 
specialized psychiatric clinic, the Internet psychiatry clinic in Stockholm, Sweden have treated 
mostly self-referred patients from the general population for depression and panic disorder 
since 2007, 61,62 and for social anxiety since 2009. 63 The treatment program for depression 
used at this clinic is based on behavioral activation, cognitive reappraisal and some worry- and 
sleep management components. The results from routine care showed that internet-based 
treatment of depression was effective for patients who received a diagnosis of depression and 
were included in treatment, which was around 50 % of people who applied for treatment. 61 
Note that there was no control condition in this study. The inclusion process at the clinic also 
excluded patients who for example presented with depressive and comorbid symptoms, but 
who didn’t meet the DSM-criteria for major depression.  
In another Swedish study, patients were randomized to either internet-treatment for depression 
given with guidance from the patients’ local primary care facility, and treatment as usual in 
primary care. 64,65 There was no difference in effect on depression symptoms between the 
internet-treatment and treatment as usual. The treatment setting used in this study differed 
substantially from the one at the Internet psychiatry clinic by using guidance from therapists at 
separate primary care units and presenting all treatment modules at once.  
In a British study, depressed patients were randomized to either one of two internet-based 
treatments for depression as an adjunct to treatment as usual in primary care, or to treatment as 
usual in primary care alone. 66 There was no evidence of better depression outcomes in the 
groups receiving an internet intervention, compared to treatment as usual alone in this study. 
This result could be explained by the fact that the grade of use of the adjunct treatments in this 
study was, despite scheduled support phone calls, very low. 66 
In a study in an Australian primary care setting, an internet-based treatment of depression and 
generalized anxiety was found to be effective when compared to a wait list-control, but this 
treatment showed increased problems with treatment adherence when given fully in primary 
care. 67 Another Australian study of a combined depression and anxiety internet intervention in 
routine care showed large effects of treatment. In this case the treatment included both a large 
degree of automated support, and support from a centralized internet-treatment clinic. 68 These 
results taken together may suggest some advantages of administering the treatment from a 
specialized clinic even if recruiting patients at the primary care level or by self-referral.  
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1.7.5 Individually tailored internet-based treatment 
Most internet-based treatments have traditionally been given with the treatment modules in a 
fixed order, and therefore also with the same treatment components for all participants. In 
contrast, in an individually tailored treatment, the different treatment components are chosen 
to build an individual treatment plan for each participant. Some possible advantages of the 
individually tailored over the disorder-specific procedure could be:  
 The possibility to treat more than one condition within one treatment, reducing the need 
for costly serial treatments. 
 The ability to include a larger share of help seeking patients in a treatment with suitable 
evidence based components by better treatment-patient matching and better handling 
of patients with comorbid conditions. 
 The boosting of treatment credibility and compliance because of a high degree of 
experienced treatment specificity and personalization. 
There is some early encouraging evidence for individually tailored internet-based treatments. 
One individually tailored treatment was found to be effective for patients in a group with mixed 
anxiety disorders and also to be effective and cost-effective in a primary care population. 69,70 
Individually tailored treatment for anxiety disorders has also showed similar results as disorder-
specific treatment for social anxiety, panic disorder and generalized anxiety. 71  
In another study, there was no difference between individually tailored treatment and disorder-
specific internet-based treatment for depression, when compared head to head regarding effects 
on depression symptoms. 72 No evidence of a difference is however not the same as evidence 
of no difference. Studies with more participants are needed to show if individually tailored 
treatment can be regarded as non-inferior to disorder-specific treatment for depression, and 
other conditions. A subgroup analysis in the above mentioned study did however suggest that 
the individually tailored treatment was possibly more effective than disorder-specific treatment 
in reducing depression for participants with many comorbid conditions. 72   
1.7.6 Remaining research questions 
Although there is a rising number of studies on psychological treatments that have included 
participants with comorbid conditions, only a minority of them actually have examined the 
effects on the conditions comorbid to the targeted main condition. 73 The effectiveness and 
cost-effectiveness of individually-tailored treatment also needs to be compared to other feasible 
treatment alternatives in primary care before we can be able to recommend broader 
implementation of this treatment type. Another question that remains to be answered about 
individually tailored treatment is which treatment components that are important for symptom 
reductions in depression and the other targeted conditions.  
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1.8 INTRODUCTION SUMMARY 
 Depression is a large societal problem. 
 Depression sufferers are heterogeneous and have many comorbid conditions, partly 
because of how depression is defined. 
 Pharmacological treatment is widespread for depression and comorbid conditions, but 
it is not effective for all, there are considerable side-effects, and patients often prefer 
psychological treatment. 
 Some kinds of psychological treatment are effective and recommended in guidelines, 
but access is low. 
 Individually tailored internet-based treatment is a treatment alternative with promising 
effects on depression and anxiety, but questions remain. 
1.9 AIMS OF THE THESIS 
The overall aims of this thesis were to compare individually tailored internet-based treatment 
to other viable treatment alternatives, and to explore which treatment components in 
individually tailored treatment that were important for specific effects on targeted conditions.   
Specific research questions were: 
 What are the effects of individually tailored internet-based treatment on depression 
levels compared to treatment as usual in primary care? (Study I) 
 What are the preliminary effects of individually tailored internet-based treatment on the 
comorbid conditions of depression? (New data) 
 Is individually tailored internet-based treatment cost-effective compared to treatment 
as usual in primary care? (Study II) 
 Is individually tailored internet-based treatment non-inferior to disorder-specific 
internet-based treatment for depression, panic disorder and social anxiety in routine 
psychiatric care? (Study III) 
 Can compliance to specific treatment components in individually tailored internet-
based treatment predict specific effects on the conditions they are meant to improve? 
(Study IV) 
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2 METHODS 
2.1 THE REGASSA-PROJECT (STUDY I-IV) 
All four studies in this thesis are based on REGASSA, a project aimed at examining feasible 
treatment alternatives for depression, anxiety and stress-related mental ill-health. The treatment 
alternatives examined in REGASSA were individually tailored internet-based treatment based 
on CBT (TAIL) and structured physical exercise (PE). These treatment alternatives were 
contrasted against the treatment as usual that the participants would receive at their primary 
care unit (TAU). REGASSA was carried out in collaboration with six Swedish county councils 
(Blekinge, Kronoberg, Skåne, Stockholm, Västmanland and Västra Götaland) and two 
universities (Karolinska Institutet and Lund university). REGASSA was approved by the 
Regional ethics review board in Stockholm (2010/1779-31/4), first preregistered at Karolinska 
Clinical Trial Registration registry (KT20110063) and later registered at German clinical trials 
(DRKS00008745). 
The REGASSA-project was funded by REHSAM, a Swedish government initiative that funded 
research projects examining effects of treatments on sick-leave and employment for patients 
with pain, or mental ill-health like depression, anxiety and stress-related conditions. The 
primary aim of the REGASSA-project as a whole was consequentially to examine the effects 
on sick-leave and employment on patients with mild to moderate depression, anxiety and 
stress-related mental ill-health. Patients with pain were not the focus of REGASSA although 
they were not excluded if they had pain comorbid to mental ill-health. This thesis will only 
mention the effects on sick-leave and employment briefly while the included studies I-IV focus 
on the effects on symptoms and costs.  
2.1.1 Participants and design 
Participants were initially recruited only at the primary care units in the six participating county 
councils. To speed up the recruitment process in Stockholm county, some of the participants 
there were recruited with the help of newspaper ads and a primary care research center (KTA 
Prim). Recruited participants were screened for at least mild symptoms of depression, and those 
who were at least 18 years old and had a Patient Health Questionnaire (PHQ-9) score of > 9 
were invited to participate. Exclusion criteria included severe somatic illness, alcohol or drug 
use disorder or severe psychiatric problems such as psychosis. A total of 946 participants were 
included between February 2011 and March 2013. Please see Figure 3 for overall trial design 
and measurement time points. 
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Figure 3. Trial design and measurement time points for the studies included in this thesis. 
TAIL, individually tailored internet-based treatment; PE, structured physical exercise; TAU, 
treatment as usual in primary care; I, Study I; II, Study II; III, Study III; IV, Study IV. 
2.1.2 Outcomes 
Clinician-rated depression (Study I and II) was assessed by a clinician at three time points 
(baseline, 3-months and 12-months after baseline) with Montgomery-Åsberg Depression 
Rating Scale (MADRS). 74 All included participants completed a battery of questionnaires at 
all three time points with the help of a clinician. These questionnaires were used in Study I and 
II and included single-item Work Ability Index (WAI) 75 which was used to measure self-rated 
work capacity, the Client Satisfaction Questionnaire-8 (CSQ-8) 76 which was used to measure 
satisfaction with treatment using both quantitative ratings and written comments, the EuroQol-
5D-3L (EQ-5D) 77 which was used to construct Quality-Adjusted Life-Years (QALYs), and 
the Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TiC-P) 78 
which was used to calculate healthcare resource use and costs in both the primary health care 
and societal perspectives. Costs and QALYs were then used to construct incremental cost-
effectiveness ratios (ICERs) as a way to compare the cost-effectiveness of TAIL or PE to TAU. 
Inclusion and baseline survey 
(I, II) 
 
Randomization 
(n=945) 
 
Online survey 1 
(III, IV) 
 
 
PE 
 
TAU 
3-month survey  
(I, II) 
3-month survey  
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12-month survey 
(II)  
 
Follow-up assessment 
(12 months) 
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(III, IV) 
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The ICERs were then compared to an often-used threshold of healthcare provider willingness-
to-pay of €21 536 (£20 000) per QALY. 79 
After the baseline survey, the participants were randomized to 12 weeks of TAIL, PE or TAU. 
Participants in the TAIL condition also completed additional online surveys before and after 
treatment (used in Study III and IV) including the following seven self-report measures (cut-
off scores used in this thesis for representing at least mild symptoms are included): 
 Depression symptoms was assessed with the Montgomery–Åsberg Depression Rating 
Scale – Self-rated (MADRS-S ; Cut-off ≥ 13). 80 
 Worry symptoms was assessed with the Penn State Worry Questionnaire (PSWQ ; 
Cut-off ≥ 45). 81 
 Panic symptoms was assessed with the Panic Disorder Severity Scale – Self report 
(PDSS-SR ; Cut-off ≥ 6). 82 
 Social anxiety symptoms was assessed with the Liebowitz Social Anxiety Scale – Self-
Rated (LSAS-SR ; Cut-off ≥ 30). 83 
 Stress symptoms was assessed with the Perceived Stress Scale – 10 item (PSS-10 ; 
Cut-off ≥ 13). 84 
 Insomnia symptoms was assessed with the Insomnia Severity Index (ISI ; Cut-off ≥ 
8). 85 
 Pain symptoms was assessed with the Multidimensional Pain Inventory (MPI ; Cut-off 
≥ 1.7). 86 
Additional assessments were also collected in all three groups at other time points by an 
automated telephone technique (Interactive Voice Response, IVR) but results from these were 
not a part of this thesis and will only be mentioned briefly.  
2.1.3 Individually tailored internet-based treatment (TAIL) 
An early version of TAIL was tested in a small clinical, unpublished pilot study with 10 
participants in 2011. After the pilot study, the treatment program was revised and finalized as 
described below.  
TAIL consisted of mandatory and optional treatment modules. A module included 
psychoeducation that was based on text and illustrations and ended with a practical homework 
assignment in the form of interactive worksheets. See Figure 3 for an example of a worksheet 
and Table 1 in Study IV for a complete list of modules in TAIL. The homework was to be 
completed by the participant within a week, and after feedback from the therapist, the next 
module was made available. Therapists aimed at limiting support and feedback to 15 minutes 
per participant and week. Therapist-support consisted in most cases of written messages, but 
sometimes also of short phone calls if needed. 
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Figure 3. Screenshot of a worksheet from the homework assignment in the module for problem 
solving. The worksheet helps the participant to break down a problem in manageable steps that 
helps the participant to formulate the problem, to try possible solutions, and then to evaluate 
the tried solutions.  
2.1.3.1 Mandatory treatment modules 
Participants had to complete the first three treatment modules to get to the individually tailored 
part of TAIL. The main components of these three modules were identification of personal 
values, behavioral activation and handling avoidance behaviors, and they were planned to be 
completed within the three first weeks of treatment. This mandatory treatment content was 
based on the depression treatment used in routine care at the Internet psychiatry clinic, 61 but 
redeveloped and adapted to also fit participants with comorbid anxiety symptoms. 
2.1.3.2 Selection of optional treatment content 
In addition to the online self-report-measures, the participants in TAIL also rated their 
recognition, as well as their subjective severity levels, of the seven types of symptoms, after 
reading a brief description of each symptom area. Before the start of the individually tailored 
part of treatment, the therapist and participant used both pre-treatment questionnaires and 
other ratings to agree on the remaining part of the treatment plan. The therapist also presented 
the proposed treatment plan during weekly group supervision sessions with all clinicians 
engaged in delivering TAIL.  
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2.1.3.3 Optional treatment modules 
The individually tailored part of treatment was mostly based on the individually tailored 
treatment for depression used in the study by Johansson and colleagues, 72 but redeveloped and 
adapted to fit within the rest of TAIL. These treatment modules were basically shortened 
versions of full internet-treatment programs for other conditions that had been tested in earlier 
disorder-specific treatment studies. The following is a list of the main symptom areas, of which 
participants had one to three in their treatment plan. There are also examples of the treatment 
content of the individually tailored modules for each symptom area. 
 Depression (continued). Treatment modules focusing on continued behavioral 
activation, and adding cognitive restructuring of depressive thoughts. This content was 
similar to the content of the depression treatment implemented in routine care with large 
effects on depressive symptoms. 61 
 Worry. Treatment modules focusing mainly on relaxation, worry exposure, problem-
solving and worry time. A somewhat similar treatment program has been tested in a 
randomized study with promising results for problems related to worry and generalized 
anxiety. 87 
 Panic. Treatment modules focusing mainly on exposure for both panic symptoms and 
agoraphobia. This content was similar to the content of the panic treatment 
implemented in routine care with large effects on panic- and agoraphobic symptoms. 62 
 Social anxiety. Treatment modules focusing mainly on exposure. This content was 
similar to the content of the social anxiety treatment implemented in routine care with 
medium-to-large effects on social anxiety symptoms. 63 
 Stress. Treatment modules focusing mainly on relaxation, mindfulness, problem-
solving and focus-shifting. A somewhat similar treatment program has been tested in a 
randomized study with promising results on perceived stress. 88 
 Insomnia. Treatment modules focusing mainly on sleep restriction and stimulus 
control. A similar treatment program has been tested in a randomized study with large 
effects on insomnia symptoms. 89 
 Pain. Treatment modules focusing mainly on relaxation and behavioral activation. A 
somewhat similar treatment program has been tested in a randomized study with 
promising results for disability associated with pain. 90 
In addition to the treatment content mentioned above there were optional modules with content 
for initiating physical exercise, assertiveness training, maintaining healthy habits and handling 
perfectionism. There were also work-related modules, developed and adapted for participants 
with different work-related problems. These modules included content for staying in contact 
with authorities, returning to work after sick-leave, handling problems at work, and finding 
new a job. The module for finding a new job was a novel internet-adaptation of Azrin and 
colleagues’ work on job finding clubs from the 1970’s. 91 Finally, there was also module for 
all patients at the last week of treatment containing summary and relapse prevention. 
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2.1.4 The comparison treatments 
2.1.4.1 Physical exercise (PE) 
Participants randomized to the PE condition in REGASSA were sub-randomized to three 
exercise intensity levels: low, medium or high intensity. The analysis of the relationship 
between exercise intensity and outcome is not included in this thesis; the results of all PE 
participants were instead analyzed together. Participants in all PE intensity groups were 
expected to attend three 60-minute group sessions per week during the 12-week treatment 
period giving a maximum of 36 hours of scheduled exercise. The intervention also included a 
weekly meeting with a personal trainer or physiotherapist, and phone reminders when not 
attending any PE sessions for a week.  
2.1.4.2 Treatment as usual (TAU) 
REGASSA was conducted in the context of the National Rehabilitation Guarantee, an 
agreement between government and county councils in Sweden during 2008-2015 in which 
adults with pain, or mental ill-health like depression, anxiety and stress-related conditions were 
to be guaranteed evidence-based interventions. This context was interpreted as that participants 
receiving TAU at their primary care unit were entitled to receive individual or group-CBT at 
their primary care unit, although not necessarily by a clinician with more experience delivering 
the method than a five-week course in CBT. How well this worked out differed greatly between 
different primary care centers. The content of the TAU-condition is for that reason handled in 
the results-section in this thesis. Study II reports the healthcare use during the treatment period 
in TAU compared to TAIL and PE.  
2.2 THE INTERNET PSYCHIATRY CLINIC BENCHMARKS (STUDY III) 
The evaluation of the treatments given in routine care at the Internet psychiatry clinic was 
approved by the Regional ethics review board in Stockholm (2011/2091-31/3). The samples 
used as benchmarks in Study III consisted of 4 869 patients receiving disorder-specific internet-
based treatment at the clinic from October 2007 to July 2017 for depression, panic disorder or 
social anxiety. These patients were mostly self-referred, and those included in treatment 
underwent a 12-week treatment for their main condition that equaled TAIL in length and 
intensity of both support and amount of text.  
The content of the disorder-specific treatments is described in detail elsewhere. 61–63 In short, 
the depression treatment focused mainly on behavioral activation and cognitive restructuring 
and outcome was the MADRS-S. 80 The panic disorder treatment focused on exposure for panic 
symptoms and agoraphobic situations and outcome was the PDSS-SR. 82 Finally, the social 
anxiety treatment focused on exposure and behavioral experiments for social situations and 
outcome was the LSAS-SR. 83 
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2.3 ETHICAL CONSIDERATIONS 
All studies were conducted with approval from an appropriate ethics review board. All 
participants gave their informed consent to participate and were informed that they could 
withdraw their participation at any time. Participants in the internet-based treatments were 
monitored weekly for suicidal ideation and were contacted if showing any sign of suicidality. 
All written communication between therapists and participants in the internet-based 
treatments were encrypted and the procedure to log in to the treatment platform used the same 
level of protection as online bank services. 
2.4 SUMMARY AND COMPARISON OF METHODS STUDY I-IV 
Both Study I and II used all three randomized groups in REGASSA. In Study I, differences 
between the three treatment groups at post-treatment were explored using analysis of 
covariance (ANCOVA) with pre-treatment depression score and self-rated work capacity 
entered as covariance factors. Pairwise comparisons were then used to explore which groups 
that differed significantly at post-treatment.  
Within- and between-group effect sizes were used to facilitate the comparison of effects 
between studies. The types of effect sizes used, Cohen’s d and Hedge’s g, are interchangeable 
(except for in very small samples where g is a more conservative estimate) and can be 
interpreted roughly as: 92 
 > 0.2 = small effect 
 > 0.5 = moderate effect 
 > 0.8 = large effect.  
In the cost-effectiveness of Study II, non-parametric bootstrapping was used to simulate 
ICERs to account for the uncertainty of the ICER point estimates. These simulated ICERs 
were then used to estimate the probabilities of the treatment alternatives being cost-effective 
compared with TAU at the chosen willingness to pay-threshold. 
While Study I and II examined all three treatment alternatives in REGASSA in randomized 
designs, Study III and IV only looked at TAIL. In Study III, TAIL was instead contrasted to 
the disorder-specific treatments of the Internet psychiatry clinic. For the comparison with the 
disorder-specific depression treatment all participants in TAIL with at least mild depressive 
symptoms were used. For the comparison with the disorder-specific panic disorder and social 
anxiety disorder treatments, only participants with a probable diagnosis of panic disorder and 
social anxiety disorder who also had at least mild symptoms on the corresponding specific 
symptom scale were used. To be classified as non-inferior to the disorder-specific benchmark 
treatment the comparison treatment needed to have a lower end of the 95 % confidence 
interval of the effect size that were at least as high as the point estimate of the the benchmark 
treatment effect size, minus the minimally clinically relevant effect (Δ). 93 The value Δ, was 
set to 0.24 following an empirically derived proposal for minimally clinically relevant effect 
for depression. 94 
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Study IV used hierarchical regression to explore if expert-rated treatment compliance could 
predict reductions on a number of specific symptom scales. Expert-rated compliance with the 
whole treatment, or with condition-specific components, was used as a predictor in the 
regression model with specific symptoms as dependent variable. The guide to scoring of 
treatment compliance in Study IV was created for this analysis and can be found in the 
supplementary material to the Study IV-manuscript included in this thesis.  
All studies used different designs and statistical analysis methods. See Table 2 for an 
overview of the methods used in Study I-IV which are also described fully in the scientific 
papers included in this thesis.  
Table 2. Summarizing comparison of methods in Study I-IV. 
 Study I 
 
Study II 
 
Study III 
 
Study IV 
 
Primary 
aim 
To evaluate the 
effects of TAIL, 
PE and TAU on 
depression 
To evaluate the costs 
and cost-effectiveness 
of TAIL and PE in 
relation to TAU 
To benchmark the 
effects of TAIL 
against disorder-
specific internet-
based treatment 
To explore if 
compliance to 
components in TAIL 
predicted specific 
symptom reductions 
Design Randomized 
controlled trial 
Randomized 
controlled cost-
effectiveness trial 
Benchmarking design 
with non-randomized 
control conditions 
Longitudinal 
correlational design 
Primary 
statistical 
analysis 
ANCOVA Non-parametric 
bootstrapping of 
ICERs 
Benchmarking of an 
effect size difference 
against a clinically 
relevant effect 
Hierarchical regression 
Primary 
outcomes 
MADRS TiC-P, QALYs MADRS-S, PDSS-
SR, LSAS-SR 
Expert-rated 
compliance, MADRS-S, 
PSWQ, PDSS-SR, 
LSAS-SR, PSS-10, ISI, 
MPI 
TAIL, individually tailored internet-based treatment; PE, structured physical exercise; TAU, treatment as usual in 
primary care; ANCOVA, analysis of covariance; ICERs, incremental cost-effectiveness ratios; MADRS, 
Montgomery–Åsberg Depression Rating Scale; TiC-P, Trimbos and iMTA questionnaire on Costs associated with 
Psychiatric illness; QALYs, Quality-Adjusted Life-Years; MADRS-S, Montgomery–Åsberg Depression Rating 
Scale – Self-rated; PSWQ, Penn State Worry Questionnaire; PDSS-SR, Panic Disorder Severity Scale – Self 
report; LSAS-SR, Liebowitz Social Anxiety Scale – Self-Rated; PSS-10, Perceived Stress Scale – 10 item; ISI, 
Insomnia Severity Index; MPI, Multidimensional Pain Inventory. 
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3 RESULTS 
3.1.1 Treatment use and satisfaction 
Please see Table 3 for a summary of treatment use and treatment satisfaction in REGASSA. 
The measurements of treatment use were not directly comparable between treatment 
alternatives. The mean results for TAIL was 3.2 hours of therapist-support per treatment, which 
translates to 16 minutes of therapist-time per participant and week, and 7.8 received modules 
out of an expected 12 (65 %). For PE, number of exercise sessions were 14.6 out of a maximum 
of 36 (41 %). TAU consisted of more use of primary care resources during the treatment period 
than TAIL and PE which also translates into higher mean costs for the primary health care 
provider. Please see Table 3 in Study II for a complete breakdown of costs, and resource use, 
during treatment. Noteworthy is that 20 % of TAU participants reported going to counselling 
sessions during the treatment period compared to 13 % of PE, and 5 % of TAIL participants, 
and that 9 % received individual CBT compared to 3 % in the PE and TAIL groups.  
The satisfaction scale CSQ-8 has a range from 8 to 32 and established cut-off scores states that 
8–13 indicates poor, 14–19 fair, 20–25 good and 26–32 excellent satisfaction. 95 With these 
cut-offs as guidelines the satisfaction with both TAIL and PE can be said to have been good, 
but  participants in the TAU condition were only fairly satisfied with their treatment. The post-
treatment survey also revealed that a majority of participants who chose to actively drop out of 
treatment did so because of dissatisfaction with the randomization outcome. 
Table 3. Summary of treatment use and satisfaction in the main REGASSA treatment 
alternatives.  
 Treatment use (95% 
CI) 
Primary care costs 
representing resource 
use during treatment 
(SE) 
Treatment satisfaction, 
CSQ-8 (95% CI) 
TAIL    
 
3.2 (2.9-3.5) support in h 
7.8 (7.2-8.4) modules 
€310 (10.9) 23.7 (22.9-24.5) 
PE 14.6 (12.6-16.6) sessions €355 (15.4) 23.6 (22.9-24.4) 
TAU - €513 (20.7) 19.5 (18.5-20.5) 
Adherence in TAIL is described with mean time in hours of therapist support and mean number of received 
modules. Adherence in PE is described as mean number of attended 1-hour exercise sessions. TAIL, individually 
tailored internet-based treatment; PE, structured physical exercise; TAU, treatment as usual in primary care; CI, 
confidence interval; SE, standard error. 
Some quotes from the satisfaction questionnaire function as illustrative examples of when 
participants receiving the different treatment alternatives were dissatisfied: 
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 “I would rather have had physical activity” (Participant in TAIL) 
 “It would have been better if it was in my language, Spanish” (Participant in TAIL) 
 “I never started training. The training times did not suit me. [...] It did not fit my work 
situation.” (Participant in PE) 
 “Too bad I could not participate the maximum in physical exercise because I got work 
elsewhere.” (Participant in PE) 
 “Far too unstructured - no overall plan.” (Participant in TAU) 
 “I have not received any treatment.” (Participant in TAU) 
 “Incompetent psychologist.” (Participant in TAU) 
3.1.2 Treatment effects (Study I) 
3.1.2.1 Effects on clinician-rated depression at post-treatment (Study I) 
All three treatment groups reduced their depression symptoms significantly from pre to post-
treatment with large effect sizes. See Table 4 for the within-group effects on clinician-rated 
depression during the treatment period. The interaction effect between treatment group and 
time was also significant with symptom reduction in TAIL and PE significantly larger than in 
TAU. All three groups also showed significant improvements in self-rated work capacity, but 
there was no significant difference between the groups.   
Table 4. Within-group effects on clinician-rated depression. 
 MADRS pre (SD) MADRS post (SD) Effect size, g (95% CI) 
TAIL 21.5 (6.7) 11.2 (7.3) 1.47 (1.29-1.66) 
PE 22.2 (6.8) 11.3 (7.9) 1.49 (1.30-1.68) 
TAU 20.9 (7.5) 13.8 (8.9) 0.88 (0.70-1.05) 
TAIL, individually tailored internet-based treatment; PE, structured physical exercise; TAU, treatment as usual in 
primary care; SD, standard deviation; g, Hedge’s g; CI, confidence interval. 
3.1.2.2 Effects on clinician-rated depression including follow-up data (previous study) 
An analysis of REGASSA not included in this thesis looked at effects on clinician-rated 
depression including the follow-up time point of 12 months after baseline. 96 Within-group 
effect sizes with 95 % confidence intervals from pre to follow-up based on data from this article 
were: TAIL, g = 1.64 (1.45-1.82); PE, g = 1.57 (1.39-1.76); and TAU, g = 1.22 (1.04-1.40). 
There were still significantly lower depression levels in the TAIL and PE groups compared to 
TAU at follow-up. Between-group effect sizes for TAIL compared to TAU were g = 0.66 (0.50-
0.82) post-treatment and g = 0.46 (0.31-0.62) at follow-up, in this analysis. Between-group 
effect sizes for PE compared to TAU were g = 0.57 (0.41-0.73) post-treatment and g = 0.24 
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(0.08-0.40) at follow-up. There were no significant differences between TAIL and PE at any 
time point. 96  
3.1.2.3 Other treatment effects in REGASSA (previous studies) 
Some other analyses of treatment effects in REGASSA not included in this thesis are also worth 
mentioning. There were no significant differences in effects on clinician-rated depression 
between the three exercise intensity levels in PE, strengthening the decision to analyze PE as 
one intervention. 97 In an analysis of the earlier mentioned IVR-data, both TAIL and PE 
improved psychological functioning and sleep better than TAU up to three months after 
treatment. 98 In the analysis of effects on sick-leave and employment, all three groups were 
associated with reductions in long-term sick leave but there were no differences between the 
participants' employment or sick-leave status in the TAIL or PE group compared to TAU. 99  
3.1.2.4 Preliminary effects of TAIL on symptoms of comorbid conditions (new data) 
Since the self-report measures that participants in the TAIL condition completed included 
scales of symptoms comorbid to depression, we can describe the TAIL participants’ comorbid 
symptoms more clearly than participants in PE and TAU. The proportion of participants in 
TAIL, before and after treatment, with a score above the pre-defined cut-off indicating at least 
mild symptoms can be found in Table 5.  
Table 5. Proportion of participants in TAIL indicating at least mild symptoms of six conditions 
comorbid to depression, before and after treatment. 
Comorbid condition Worry Panic Social 
anxiety 
Stress Insomnia Pain 
Proportion ≥ Mild symptoms, 
Pre-treatment 
88% 42% 66% 96% 83% 60% 
Proportion ≥ Mild symptoms, 
Post-treatment 
70% 24% 45% 78% 56% 48% 
 
The change of self-rated symptom levels from pre to post-treatment in the whole sample with 
complete online self-report measures translated into the following within-group effect sizes 
(Hedge’s g) with confidence intervals, found in Table 6. When we in Study IV examined the 
subgroups of participants with a probable diagnosis, or higher degree of problem severity, of 
the specific comorbid condition, the symptom reductions and within-group effect sizes were 
generally higher than in the whole sample seen in Table 6. This was especially especially the 
case for participants with conditions that were not as common in the sample such as Panic 
(effect on PDSS-SR in subgroup panic, g = 1.01) and Social anxiety (effect on LSAS-SR in 
subgroup social anxiety, g = 0.73). See Table 2 in Study IV for the complete list of effects in 
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the subgroups. The proportion of participants who had higher self-reported symptom levels 
after treatment (deteriorated) on each scale is also presented below in Table 6. For comparison, 
the proportion who deteriorated on self-rated depression (MADRS-S) was 12 %. 
Table 6. Change of mean comorbid symptom levels including within-group effect sizes and 
proportion of participants who deteriorated from pre- to post-treatment. 
Comorbid 
condition 
Scale n Pre-treatment, 
m (SD) 
Post-treatment, 
m (SD) 
Effect size, g (95% 
CI) 
Proportion 
deteriorated 
Worry PSWQ 207 58.2 (11.9) 52.0 (12.2) 0.51 (0.31-0.70) 23% 
Panic PDSS-SR 204 5.1 (5.2) 3.1 (4.1) 0.44 (0.24-0.64) 20% 
Social 
anxiety 
LSAS-SR 204 42.4 (28.9) 34.0 (25.4) 0.31 (0.11-0.50) 32% 
Stress PSS-10 203 24.0 (6.2) 18.6 (7.0) 0.82 (0.62-1.02) 20% 
Insomnia ISI 204 13.6 (6.3) 9.4 (6.5) 0.66 (0.46-0.85) 17% 
Pain MPI 207 3.2 (3.2) 2.8 (3.2) 0.13 (-0.06-0.32) 35% 
PSWQ, Penn State Worry Questionnaire; PDSS-SR, Panic Disorder Severity Scale – Self report; LSAS-SR, 
Liebowitz Social Anxiety Scale – Self-Rated; PSS-10, Perceived Stress Scale – 10 item; ISI, Insomnia Severity 
Index; MPI, Multidimensional Pain Inventory; g, Hedge’s g; CI, confidence interval. 
3.1.3 Cost-effectiveness (Study II) 
The TAU group had a higher mean resource use during treatment than TAIL and PE as we 
saw in Table 3. When adding the calculated costs of the TAIL and PE interventions however, 
these treatment alternatives became more costly for the primary health care provider (Cost 
(SE)): TAIL, €811 (11.5); PE, €999 (18.7); TAU, €513 (20.7). When switching to the cost 
perspective of the society as a whole and also adding cost data for the whole year since 
baseline, TAIL and PE were still more costly than TAU (Cost (SE)): TAIL, €11685 (586.8); 
PE, €11890 (731.1); TAU, €10623 (809.9).  
Both TAIL and PE produced more QALYs than TAU during the 12 month follow up-period 
(TAIL, 0.034 more QALYs than TAU; PE, 0.033 more QALYs than TAU). Together with the 
cost data, this led to the incremental cost per QALYs (ICERs) as seen in Table 7. At the health 
care provider willingness-to-pay threshold of €21 536 per QALY, the probability of TAIL 
being cost-effective versus TAU was 90 % and for PE versus TAU it was 76 %. 
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Table 7. Incremental cost per QALY for TAIL and PE compared to TAU. 
 Incremental cost per QALY: 
primary healthcare perspective 
Incremental cost per QALY: 
1-year societal perspective 
TAIL vs. TAU €8817 €31471 
PE vs. TAU €14571 €37974 
TAIL, individually tailored internet-based treatment; PE, structured physical exercise; TAU, treatment as usual in 
primary care; QALY, Quality-Adjusted Life-Year.  
3.1.4 Non-inferiority to disorder-specific routine care benchmarks (Study III) 
For the participants in TAIL, the within-group effect size for depression was above the non-
inferiority margin based on the disorder-specific depression group (Table 8). The effect size 
of the subgroup in TAIL with probable panic was slightly lower than the effect of the 
disorder-specific panic group and not above the non-inferiority margin. The effect size of the 
subgroup in TAIL with probable social anxiety was similar to the effect of the disorder-
specific social anxiety group, but the lower end of the confidence interval was not above the 
non-inferiority margin. 
Table 8. Comparison off within-group effect sizes between disorder-specific benchmark 
treatments and the TAIL intervention.  
Condition and group Effect size, d Benchmarking 
comparison 
DS-depression 1.35 d – Δ = 1.11 
TAIL-depression 1.33 95% CI = 1.14-1.52 
DS-panic 1.47 d – Δ = 1.23 
TAIL-panic 1.11 95% CI = 0.66-1.56 
DS-social anxiety 0.81 d – Δ = 0.57 
TAIL-social anxiety 0.74 95% CI = 0.27-1.21 
TAIL-panic and TAIL-social anxiety were the subgroups of TAIL with a probable diagnosis of panic disorder or 
social anxiety disorder, respectively. If the lower end of the confidence interval of the TAIL effect was higher than 
the point estimate of the disorder-specific effect minus Δ = 0.24, TAIL was considered non-inferior to disorder-
specific treatment for that condition. All symptom scores used to calculate effect sizes were self-rated. DS, 
disorder-specific benchmark treatment; TAIL, individually tailored internet-based treatment; d, Cohen’s d; CI, 
confidence interval. 
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3.1.5 The relationship between treatment compliance and symptom 
reductions (Study IV) 
Expert-rated scores of treatment compliance to the whole TAIL intervention (Overall 
Compliance) predicted reductions on self-rated depression (p < .001) and explained 15 % of 
the outcome variance. Expert-rated scores of treatment compliance of the specific 
components for a condition (Specific Compliance) only predicted reductions on specific 
symptoms for participants with social anxiety, stress and insomnia, but not for worry, panic 
and pain. Specific Compliance with the stress and insomnia components were also significant 
predictors of reductions in self-rated depression symptoms. 
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4 GENERAL DISCUSSION 
4.1 PRIMARY FINDINGS 
The overall aims of this thesis were to compare TAIL to other viable treatment alternatives, 
and to explore which treatment components in TAIL that were important for specific effects 
on the targeted conditions. TAIL compared well with the other treatment alternatives and the 
importance of specific treatment components differed between the conditions included in the 
intervention. The following is a discussion of the implications of these results. 
4.1.1 Treatment use and satisfaction 
The results on treatment use of TAIL indicates that overall treatment adherence was similar 
to the disorder-specific internet-based depression in routine care (7.8 received modules out of 
an expected 12 for 12 weeks of TAIL corresponding to 65 %, versus 7.2 received modules 
out of an expected 10 for 12 weeks of disorder-specific treatment corresponding to 72 %) 61  
It is not possible to do a direct comparison between the treatment use of TAIL with that of 
PE, but use of resources in the PE condition of REGASSA was shown to be rather high in the 
Study II calculations, which gave a somewhat higher mean estimated treatment cost than 
TAIL. The high resource use in PE was probably a result of the weekly physiotherapist 
sessions and phone reminders for inactivity making the PE condition of REGASSA a rather 
ambitious intervention compared to Exercise On Prescription, and similar concepts for 
primary care. 100 
Study II also showed that resource use in primary care was higher for TAU than for TAIL 
and PE during the treatment period, but only a minority of participants in TAU actually 
received an evidence-based psychological intervention, or even supportive counselling. This 
is a testament to the shortcomings of the experimental National Rehabilitation Guarantee, 
where participants were to be guaranteed to receive evidence-based psychological 
interventions, such as individual or group-CBT, in primary care. 
Treatment satisfaction with TAIL and PE was almost as high as with disorder-specific 
depression treatment despite the occurrence of dissatisfaction with the outcome of 
randomization to treatment in REGASSA (mean CSQ-8 (95% CI) score of TAIL 23.7 (22.9-
24.5) and PE 23.6 (22.9-24.4), compared to mean CSQ-8 score of 24.5 for disorder-specific 
depression treatment). 61 Satisfaction with TAU however, was much lower at mean CSQ-8 
(95% CI) score 19.5 (18.5-20.5). This comparatively high dissatisfaction with TAU could be 
a nocebo effect of being randomized to what often appeared as the inferior treatment 
alternative, 101 and sometimes an effect of being randomized to an alternative that, as revealed 
by the quotes, contained bad, or no actual treatment.  
 28 
4.1.2 Treatment effects 
4.1.2.1 Depression 
The within-group effect of TAIL on clinician-rated depression symptoms was g = 1.47 in 
Study I. This effect is based on a pre-treatment measurement made before randomization 
which can somewhat inflate the effect estimate. The within-group effect of TAIL on self-
rated depression was however based on the pre-treatment measurement made after 
randomization, adjacent to treatment start. This estimate was d = 1.33 in Study III. 
Both these within-group effects were in any case large, and even slightly larger than in an 
earlier study of a similar, but disorder-specific treatment, and the effect seen in other guided 
internet interventions for depression. 61,102,103 More importantly, the effects of TAIL were 
significantly larger than the effects of TAU, and this difference in effect was at least of a 
clinically relevant size (≥ 0.24 effect size). 94 As noted in the introduction, other studies of 
internet-based treatment for depression has not been able to conclude superiority over 
treatment as usual in primary care. 64,66 This difference could be a result of the participants 
higher use of the internet-based intervention in REGASSA compared to the other primary 
care studies, but it could also be a result of the shortcomings of the TAU-condition in 
REGASSA. Still, TAU in REGASSA was ecologically valid as it really was treatment as it 
usually were in Swedish primary care, 2011 to 2013. 
Although there were no significant differences between TAIL and the other treatment 
alternative being evaluated, PE, this does not mean that TAIL and PE necessarily had 
equivalent effects on depression. If we exploratively use the within-group effect sizes of 
TAIL and PE and apply the benchmarking procedure of Study III, TAIL is non-inferior to PE 
both at post-treatment and at follow-up. PE is non-inferior to TAIL at post-treatment, but we 
can no longer conclude non-inferiority at follow-up when using TAIL as the benchmark. On 
the other hand, to really be able to conclude equivalence or non-inferiority between TAIL and 
PE, a prospectively designed trial with that purpose would have been preferable.  
4.1.2.2 Worry 
The within-group effect sizes for symptoms of worry were moderate, both for the whole 
sample (Table 6) and for the subgroup with probable GAD (Table 2 in Study IV). Earlier 
studies of disorder-specific internet-based treatment for GAD has demonstrated larger effects 
on worry symptoms than TAIL. 87,103,104  
4.1.2.3 Panic 
The within-group effect size for panic symptoms was small for the whole sample, but large in 
the subgroup with probable panic disorder. The within-group effect size for the subgroup was 
very similar to the effect size in the earlier study of a similar, but disorder-specific, internet-
based treatment for panic disorder, and to the effects on panic seen in a meta-analysis on 
internet interventions. 62,103 As we shall see in the direct comparison of Study III however, 
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disorder-specific panic treatment seemed to have a slight advantage, although not statistically 
significant.  
4.1.2.4 Social anxiety 
The within-group effect size for social anxiety symptoms was small for the whole sample, but 
moderate in the subgroup with probable social anxiety disorder. The within-group effect size 
for the subgroup was similar to the effect size in the earlier study of a disorder-specific 
internet-based treatment for social anxiety disorder, and to effects on social anxiety seen in a 
meta-analysis. 63,103  
4.1.2.5 Stress 
The within-group effect sizes for symptoms of stress were large, both for the whole sample 
and for the subgroup with a higher degree of perceived stress. These effect sizes were slightly 
smaller than those seen in earlier internet-based treatments solely for stress. 88,105  
4.1.2.6 Insomnia 
The within-group effect size for insomnia symptoms was moderate for the whole sample, but 
large in the subgroup with probable insomnia. The effect sizes were similar to effect sizes of 
a meta-analysis of internet-based insomnia treatment. 106 These within-group effect sizes 
were on the other hand much smaller than the very large effects seen in an earlier similar, but 
disorder-specific, guided internet-based treatment for insomnia. 89 The effect size for the 
subgroup with probable insomnia was however very similar to the effect size of a similar, but 
disorder-specific, insomnia treatment given to patients with comorbid insomnia and 
depression which implies that TAIL can be as effective as disorder-specific treatment for a 
population with concurrent insomnia and depression. 107  
4.1.2.7 Pain 
The within-group effect size for symptoms of pain was minimal, with the confidence interval 
overlapping zero, for the whole sample. For the subgroup with a higher degree of pain the 
within-group effect size was small. This small effect-size was comparable in size to the small 
effects compared to waiting list-conditions seen in a review of internet-based pain 
interventions. 108  
4.1.3 Cost-effectiveness 
The result of Study II that TAIL is probably cost-effective in the health care provider 
perspective at the willingness to pay-threshold of €21 536 (£20 000) per QALY was similar to 
other cost-effectiveness trials of internet-based treatments for depression, 109–111 strengthening 
the case for implementation of TAIL in routine care. Cost per QALY was higher in the societal 
perspective of Study II, but can still considered as moderate costs in the Swedish context.  
The cost-effectiveness results for TAIL compared to TAU in Study II depends a great deal on 
the conservatively estimated intervention cost. To explore a scenario with less conservatively 
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estimated costs we can do a kind of reversed sensitivity analysis using halved intervention 
costs. If the costs of TAIL were to be reduced by 50 %, by for example increased automation 
of therapist-support, TAIL would dominate TAU in cost-effectiveness in the health care 
perspective, i.e. TAIL would be both cheaper and more effective than TAU. The probability 
for TAIL to be cost-effective compared to TAU at the willingness to pay-threshold of €21 536 
per QALY would then also be 100 %. This explorative reasoning can function as incentive to 
keep striving to lower the costs of TAIL. Previous research has shown that even a small 
procedure change in internet-based treatment, can lead to considerably lowered costs with 
retained effects. 112 
4.1.4 Non-inferiority to disorder-specific routine care benchmarks 
The non-inferiority to the well-established disorder-specific depression treatment is another 
argument in favor of implementing TAIL in routine care. The inability to attain non-
inferiority to the disorder-specific benchmarks for panic disorder or social anxiety disorder 
was on the other hand slightly discouraging. The subgroups of TAIL used in these 
comparisons were rather small, so the result could partly be due to low statistical power. Two 
previous studies of internet-based treatment for panic disorder and social anxiety disorder did 
not find any differences in effect between a transdiagnostic and a disorder-specific approach. 
113,114 One possibly decisive difference between these studies and REGASSA was that the 
inclusion criteria in REGASSA was solely based on depression symptoms, while the studies 
of transdiagnostic versus disorder-specific treatment, used condition-specific inclusion 
criteria for panic and social anxiety symptoms. In any case, the conclusions from REGASSA 
should be restricted to be about patients with at least some depressive symptoms.  
4.1.5 The relationship between treatment compliance and symptom 
reductions  
The structured scoring of treatment compliance in Study IV was a novel method created for 
this analysis but hopefully useful in other analyses, and to other researchers, in the future. The 
guide to compliance scoring can be found in the supplement to Study IV. The following is a 
discussion of the results from Study IV together with some preliminary clinical 
recommendations based on all results. 
4.1.5.1 Depression 
The fact that overall compliance to TAIL were related to reductions on depression symptoms 
supports that working with the treatment content had an effect on depressive symptoms, 
although caution about causal conclusions always needs to be pointed out in correlational 
designs like Study IV. Specific compliance to components for stress and insomnia were also 
related to better depression outcomes which can be interpreted as these components being 
important to add to any internet-based depression treatment, where comorbid symptoms of 
stress and insomnia are high. 
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4.1.5.2 Worry 
The earlier established moderate within-group effect sizes of TAIL on worry symptoms, 
together with the rather small association between overall compliance and specific symptom 
reductions, and no association between specific compliance and specific symptom reductions, 
leads us to fairly disappointing conclusion on the worry components in TAIL. Although 
depressed participants in TAIL reduced their worry symptoms significantly, there are no clear 
advantages of TAIL over a transdiagnostic treatment approach without individual tailoring. 
Based on these data compared to previous data on GAD-patients, TAIL cannot be 
recommended as a replacement for a disorder-specific GAD-treatment.  
4.1.5.3 Panic 
Overall compliance, and compliance to transdiagnostic and nonspecific components in TAIL 
were related to considerable reductions in panic symptoms, but specific compliance to the panic 
components was not. We therefore need to conclude that although depressed participants in 
TAIL seemed to reduce their panic symptoms considerably, there was no clear advantages of 
tailoring specific panic modules. Also, because of the possibly lower within-group effects, 
TAIL cannot be recommended as a full replacement for a disorder-specific panic disorder-
treatment based on this study. Another suggestion for treating patients with concurrent panic 
and depressive symptoms, based on these results, would be a transdiagnostic anxiety-treatment 
including components on exposure and avoidance behaviors. 
4.1.5.4 Social anxiety 
The result from Study IV that the specific compliance was related to specific outcomes for 
subgroup with comorbid social anxiety in TAIL leads us to conclude that there is some 
preliminary evidence of advantages with adding tailored content on social anxiety to the 
treatment, and together with the magnitude of the effect sizes maybe even that TAIL can lead 
to sufficient reductions in social anxiety symptoms compared with disorder-specific treatment, 
for patients with both depression and social anxiety. Since the correlational nature of study IV 
and the small and underpowered subgroup with social anxiety, this preliminary outcome needs 
to replicated with more patients and a randomized design. 
4.1.5.5 Stress 
The results that specific compliance with the components associated with handling stress in 
TAIL were related to reductions in both perceived stress and depression symptoms leads us to 
the preliminary conclusion that the tailored stress content in TAIL is important for depressed 
participants with high levels of stress, both for their stress symptoms and depression 
symptoms. Since stress is such a common comorbid condition in this population, the tailoring 
of stress components can be preliminary recommended in internet-based depression 
interventions. TAIL should however not be recommended as an intervention for patients 
presenting only with stress and not depression based on this data, since all participants in 
TAIL had comorbid depressive symptoms. 
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4.1.5.6 Insomnia 
As with stress, the results from Study IV indicated that specific compliance with the insomnia 
components in TAIL were related to reductions in both insomnia symptoms and depression 
symptoms. This, together with the high concurrence of insomnia and depression symptoms in 
the population, leads us to the conclusion that the tailoring of insomnia components can be 
preliminary recommended in internet-based depression interventions. That the patients’ 
involvement in the main components in psychological treatment for insomnia, sleep restriction 
and stimulus control, is important for reductions in insomnia symptoms replicate earlier 
findings from guided self-help. 59 The results from Study IV also highlight the importance of 
improving sleep as a means to reducing symptoms of depression, which strengthens the 
conclusions from earlier research on internet-based treatment for patients with insomnia and 
depression. 107 Since many findings in psychological science are hard to replicate, 115 these 
findings on insomnia treatment actually appear as unusually stable.  
4.1.5.7 Pain 
Since neither overall compliance, nor specific compliance to the pain components in TAIL, 
were related to reductions in pain or depression symptoms, we can conclude that the 
individual tailoring of pain components was unnecessary for the patient group in TAIL, and 
that patients with pain may need specific pain interventions to reduce pain symptoms. This 
can possibly be explained by that, although concurrent pain symptoms were high in TAIL, 
the intervention was probably not viewed as a credible pain intervention by the participants. 
The small effect on pain symptoms was because of symptom reductions in patients with low 
initial levels of pain, while participants with more severe pain did not improve at all. The 
results from Study IV do however show that working with the other components in treatment 
seemed to lead to symptom reductions in depression, even for participants with pain. In 
addition, it can be argued that reductions in pain symptoms should not be the outcome in pain 
interventions, which should instead focus on for example, increased psychological flexibility. 
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4.2 STRENGTHS AND LIMITATIONS 
Each study included in this thesis include discussions of their respective strengths and 
limitations.  Here we will briefly discuss some of the strengths and limitations of the thesis as 
a whole. 
4.2.1 Strengths 
 In comparison to other randomized trials of psychological treatment, a strength with 
REGASSA was the large amount of participants leading to a reduced risk of type II 
errors, i.e. false negative findings. 
 Another strength with REGASSA was the use of, at least partly, credible treatment 
alternatives, and not waiting list-controls that are at great risk of inducing nocebo 
effects. 
  33 
 A third strength with REGASSA was the high ecological validity of the treatments. By 
using treatment alternatives set in routine care, the results have a high degree of 
generalizability to routine care for future implementation. 
4.2.2 Limitations 
 A limitation in Study I-IV was the existence of missing data. This issue was handled in 
different ways in the different studies. For Study I, some patients with missing post 
assessments did reserve interviews including the most important outcome 
measurements, such as MADRS, bringing the response rate of these main outcomes up 
to an acceptable 78 %.  In Study II the procedure of multiple imputation was necessary 
because of diverse missing data in many different variables. Study III used generalized 
estimating equations for better handling of missing data points, while Study IV used a 
complete case analysis, with a separate analysis of participants with and without 
missing data points, that can be found in the supplement of Study IV.   
 Despite using real treatment alternatives, and not waiting list-conditions, a limitation of 
Study I and II is the already mentioned nocebo effects of randomization, illustrated by 
quotes from the credibility questionnaire. The impact of this limitation is partly reduced 
by the fact that the dissapointment of being randomized to TAIL or PE were seen in 
both these groups. There were participants in TAIL that had preferred to receive PE 
and participants in PE that had preferred to receive TAIL. 
 Since the analyses in Study III and IV lacked a control condition, there was no control 
for the effect of spontaneous recovery, measurements or the passing of time, when for 
example estimating within-group effect sizes. For the outcome on depression 
symptoms, the results of the TAU control condition of Study I and II supports the 
conclusion that the effects go beyond spontaneous recovery, while for the comorbid 
conditions the conclusions by necessity have to be preliminary. The similarity of some 
within-group effect sizes to effect sizes in previous research partly reduces this 
limitation. 
 Similarly, in the correlational design of Study IV, the possible existence of confounding 
variables, influencing both compliance and outcome, cannot be completely controlled 
for. The found relations between compliance and outcome are not evidence of causal 
relations, but together with some earlier findings in randomized studies these results 
seem at least partly credible. These preliminary results can also generate hypotheses for 
future testing.   
 Although the generalizability to routine care situations probably is high, it has to be 
remembered that REGASSA was carried out in a Swedish primary care context which 
is perhaps not fully generalizable to other countries. How internet interventions and 
physical exercise are perceived as credible interventions for depression can be 
culturally dependent.   
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4.3 FUTURE DIRECTIONS 
Hopefully, the results in this thesis can stimulate further research on individually tailored 
internet-based treatment. Here are some possible directions. 
 What is the exact role of guidance, and how minimal can guidance be for effects to be 
maintained? There are already some results and ideas on how to use for example 
automated messages to enhance treatment compliance in treatments initiated by a 
clinician, but otherwise unguided. 117 
 What are the effects of specific components in treatment, down to the smallest building 
blocks? Dismantling studies with randomized and factorial designs will deepen our 
knowledge and guide us to build more efficient treatments packages. 
 Can we enhance TAIL by adding treatment components for more conditions? Some 
evidence for example, suggest that alcohol use causes depression symptoms more than 
depression symptoms causes alcohol use. 118 The addition of modules on alcohol use 
would probably help the patients with concurrent depression and problematic alcohol 
use. Other examples of interesting conditions to add components for would be 
loneliness, procrastination behaviour, and intrusive memories. 
 How can we gather weekly symptom ratings of many specific conditions without 
increasing the work load of patients filling out the assessment forms? There are already 
a number of very brief scales, such as the PHQ-2 for depression, 119 and mini-SPIN for 
social anxiety. 120 By constructing and testing new brief scales, with acceptable 
sensitivity to change, we can keep track of specific symptom changes week by week 
more easily. 
 How can we overcome the challenges of implementing an individually tailored 
treatment in a health care system with up and running procedures made for disorder-
specific treatments? Some clinicians working with implementatied internet-based 
treatments, experience problems with the current technology being inflexible for 
patients without a distinct primary condition, or that stigma is a barrier for patients to 
self-refer to treatment. 121 More research on implementation can help clinics to create 
simpler inclusion procedures for individually tailored treatments that possibly both 
reduces health care administration and patient stigma.  
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5 CONCLUSIONS 
This thesis provides support for the implementation of individually tailored internet-based 
treatment (TAIL) for patients with depression and comorbid conditions. More specifically, the 
thesis has demonstrated that: 
 TAIL leads to larger reductions in depression symptoms than treatment as usual in 
primary care, and participants are also more satisfied with their treatment. There were 
however no differences in effect compared to structured physical exercise.  
 TAIL does not seem to help much for participants with comorbid symptoms of pain, 
but reductions in worry-, panic-, social anxiety-, stress- and insomnia symptoms were 
considerable, at least for participants that had problematic symptoms of these 
conditions at treatment start. 
 When choosing treatment between TAIL and treatment as usual in primary care, it is 
probable that TAIL is the more cost-effective alternative for the health care provider.  
 TAIL is as effective as the disorder-specific internet-based treatments for depression 
already used in routine care. There is insufficient evidence to conclude if TAIL is as 
effective as disorder-specific treatment for panic disorder and social anxiety disorder, 
but there is suggestive evidence that disorder-specific panic treatment is superior for 
clear cases of panic disorder. 
 Specific treatment components in TAIL for stress and insomnia were associated with 
both specific symptom reductions, and reductions in depression symptoms. These 
treatment components should not be ignored when treating patients with depression and 
these comorbid conditions. Specific treatment components for pain where not 
necessary for symptom reductions, indicating that these components were redundant.   
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